(Q47348380)

English

Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized c

scientific article published on 9 November 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

Durable efficacy of liraglutide in patients with type 2 diabetes and pronounced insulin-associated weight gain: 52-week results from the Effect of Liraglutide on insulin-associated wEight GAiN in patients with Type 2 diabetes' (ELEGANT) randomized c (English)

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

H M de Wit

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

G M Vervoort

2

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

H J Jansen

3

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

B E de Galan

4

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

C J Tack

5

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

language of work or name

0 references

publication date

9 November 2015

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

Journal of Internal Medicine

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

279

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

3

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

283-292

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Contribution of change in glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Diabetes-related distress, insulin dose, and age contribute to insulin-associated weight gain in patients with type 2 diabetes: results of a prospective study

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Exenatide therapy in insulin-treated type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Assessment of diabetes-related distress

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin-secreting capacity

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Defining criteria for the introduction of liraglutide using the glucagon stimulation test in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Retrospective analysis of safety and efficacy of insulin-to-liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β-cell function.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26-week extension to a 26-week main trial

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Weight change with liraglutide and comparator therapies: an analysis of seven phase 3 trials from the liraglutide diabetes development programme.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

How to screen for depression and emotional problems in patients with diabetes: comparison of screening characteristics of depression questionnaires, measurement of diabetes-specific emotional problems and standard clinical assessment.

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Depression symptoms and antidepressant medicine use in Diabetes Prevention Program participants

1 reference

https://api.crossref.org/works/10.1111%2FJOIM.12447

21 January 2018

Identifiers

10.1111/JOIM.12447

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/26553486

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47348380&oldid=1424921693"